Technology transfer: agreement LFB – STROVI (Malaysia)
In the foreground Christian Béchon and Datuk Awalan Aziz, president of STROVI.
In the background Nicole Bricq, Minister of Foreign Affairs, Mustapa Mohamed, Malaysian Minister of International Trade and Industry and Jean-Paul Bacquet,
Member of Parliament and President of Ubifrance.
Signing Ceremony of « Licensing and Technology Transfer Agreement » between LFB group and STROVI Tel.
Kuala-Lumpur, Malaysia, july 29, 2013- LFB group and STROVI Tel Sdn.Bhd today announced the signature of a licensing and technology transfer agreement.
STROVI Tel intends to build and operate a plasma fractionation facility with the primary goal to Toll Fractionate plasma collected in Malaysia. STROVI Tel has submitted its intention to the Malaysian government under the Public Private Partnership (« PPP ») initiative. As the negotiations with the Malaysian government have not been concluded yet, STROVI Tel is not able to divulge further details of its proposal. STROVI Tel will also target some others countries as « toll manufacturing » clients.
Plasma fractionation is a very strategic industry whereby a particular country would be able to process it’s resources of plasma into plasma derived medicines. With the establishment of this facility, that country would be able to process a higher quantity of its plasma and reduce dependence on commercially processed plasma derived medicines which are highly priced. This facility would to a certain extend make that country be self-sufficient in the supply of these plasma derived medicines.
STROVI Tel’s technology partner is LFB (Laboratoire francais du Fractionnement et des Biotechnologies) of France. LFB group is a French state-owned biopharmaceutical company having been in the fractionation industry for almost 20 years. Intended fractionation technology would be cohn ethanol backbone and chromatography. LFB group would provide STROVI Tel with the technical know-how on the process design, protocols, requirements as well as on the job training for STROVI Tel personnel on the operation and maintenance of the facility. STROVI would also have access to LFB group’s EU compliant registered product dossiers.
LFB group is a biopharmaceutical group that develops, manufactures and markets medicinal products for the treatment of serious and often rare diseases in several major therapeutic areas:immunology,intensive care and hemostasis. LFB group is the leading manufacturer of plasma-derived medicinal products in France and the 5th player worldwide and is also among the leading European companies for the development and production of new-generation proteins and treatments based on biotechnologies.
The LFB Group is pursuing a growth strategy that seeks to extend its activities at the international level and develop innovative therapies. To that end, the LFB Group currently markets its products in 20 countries around the world with a global turnover of euros 466 million in 2012.
About STROVI TEL Sdn.Bhd:
STROVI Tel Sdn Bhd (« STROVI ») was incorporated in 2009 and its sole purpose is to build, operate and own a plasma fractionation plant producing four products : Anti Haemophilia Factor VIII, Prothrombin Complex Concentrate, Human Albumin and Intravenous Human Immunoglobulin (IVIG). These plasma derived medicines extracted from human plasma are widely used for bleeding disorder, intensive care and Immune deficiency patients. STROVI Tel intend to invest about RM 700.0 million for the development of this state-of-the-art facility at Bandar Teknologi Enstek, Nilai, Negeri Sembilan. The facility would be built on a 15 acre plot of land and would comprise a full fledge processing facility as well as research labs. The plant is expected to process about 100 batches of plasma and one batch is equivalent to 3,000 litres. The proposed facility would be constructed and designed to be international GMP compliant and produced EMA (« European Medicines Agency ») compliant products. Upon operation in 3-4 years time, STROVI Tel’s plasma fractionation plant would be among the only few in Asia with the exception of Japan, South Korea and China.